CO2018011087A2 - Tratamiento de dermatitis atópica canina - Google Patents

Tratamiento de dermatitis atópica canina

Info

Publication number
CO2018011087A2
CO2018011087A2 CONC2018/0011087A CO2018011087A CO2018011087A2 CO 2018011087 A2 CO2018011087 A2 CO 2018011087A2 CO 2018011087 A CO2018011087 A CO 2018011087A CO 2018011087 A2 CO2018011087 A2 CO 2018011087A2
Authority
CO
Colombia
Prior art keywords
treatment
atopic dermatitis
compositions
cad
prevention
Prior art date
Application number
CONC2018/0011087A
Other languages
English (en)
Inventor
Kaspars Tars
Original Assignee
Benchmark Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benchmark Animal Health Ltd filed Critical Benchmark Animal Health Ltd
Publication of CO2018011087A2 publication Critical patent/CO2018011087A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14023—Virus like particles [VLP]

Abstract

RESUMEN La presente invención se refiere a composiciones, composiciones inmunogénicas o de vacuna y composiciones farmacéuticas para la prevención o tratamiento de dermatitis atópica canina (CAD). Además, la invención proporciona métodos para la prevención o tratamiento de CAD. Las composiciones de la invención inducen respuestas inmunes eficientes, en particular respuestas de anticuerpos, en perros y, por lo tanto, son útiles para el tratamiento y/o prevención de CAD.
CONC2018/0011087A 2016-04-27 2018-10-16 Tratamiento de dermatitis atópica canina CO2018011087A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16167264 2016-04-27
PCT/EP2017/059977 WO2017186813A1 (en) 2016-04-27 2017-04-26 Treatment of canine atopic dermatitis

Publications (1)

Publication Number Publication Date
CO2018011087A2 true CO2018011087A2 (es) 2019-02-08

Family

ID=56024099

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0011087A CO2018011087A2 (es) 2016-04-27 2018-10-16 Tratamiento de dermatitis atópica canina

Country Status (17)

Country Link
US (1) US10946078B2 (es)
EP (1) EP3448422A1 (es)
JP (2) JP7039561B2 (es)
KR (2) KR20220162800A (es)
CN (2) CN116688110A (es)
AR (1) AR108333A1 (es)
AU (2) AU2017256727B2 (es)
BR (1) BR112018071965A2 (es)
CA (1) CA3019653A1 (es)
CL (1) CL2018002960A1 (es)
CO (1) CO2018011087A2 (es)
EA (1) EA201892003A1 (es)
MX (1) MX2022009171A (es)
NZ (1) NZ747512A (es)
UA (1) UA126852C2 (es)
WO (1) WO2017186813A1 (es)
ZA (1) ZA201806503B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018383708B2 (en) * 2017-12-11 2023-10-26 Ubi Ip Holdings Peptide immunogens of IL-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
AU2019234220A1 (en) 2018-03-16 2020-09-10 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
BR112020017715A2 (pt) * 2018-03-16 2020-12-29 Zoetis Services Llc Vacinas de peptídeo contra interleucina-31
CA3121843A1 (en) * 2018-12-20 2020-06-25 Saiba AG Virus-like particles of cmv modified by fusion

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
DK1450856T3 (da) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
ZA200701713B (en) * 2004-09-21 2008-07-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
MX2007003171A (es) * 2004-09-21 2007-05-23 Cytos Biotechnology Ag Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
AU2006214404B2 (en) * 2005-02-14 2012-03-08 Bristol-Myers Squibb Company Methods of treating skin disorders using an IL-31RA antagonist
JP5484732B2 (ja) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子
WO2008112674A1 (en) * 2007-03-12 2008-09-18 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
US8465756B2 (en) * 2009-08-12 2013-06-18 National Health Research Institutes Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2014107344A1 (en) * 2013-01-04 2014-07-10 Bristol-Myers Squibb Company Positive allosteric modulators and silent allosteric modulators of the opioid receptor
WO2015042596A1 (en) 2013-09-23 2015-03-26 Kindred Biosciences, Inc Treatment of atopic dermatitis in non-human animals
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié

Also Published As

Publication number Publication date
EA201892003A1 (ru) 2019-05-31
AU2017256727A1 (en) 2018-11-15
US20190209668A1 (en) 2019-07-11
JP7273214B2 (ja) 2023-05-12
US10946078B2 (en) 2021-03-16
CA3019653A1 (en) 2017-11-02
AU2017256727B2 (en) 2022-09-29
JP2019515957A (ja) 2019-06-13
KR20220162800A (ko) 2022-12-08
AU2022291431A1 (en) 2023-03-30
EP3448422A1 (en) 2019-03-06
CL2018002960A1 (es) 2019-01-25
UA126852C2 (uk) 2023-02-15
MX2022009171A (es) 2022-08-17
ZA201806503B (en) 2019-07-31
KR102469478B1 (ko) 2022-11-23
CN109562156A (zh) 2019-04-02
CN109562156B (zh) 2023-03-10
WO2017186813A1 (en) 2017-11-02
JP2022078254A (ja) 2022-05-24
JP7039561B2 (ja) 2022-03-22
CN116688110A (zh) 2023-09-05
BR112018071965A2 (pt) 2019-03-06
KR20190003948A (ko) 2019-01-10
NZ747512A (en) 2023-05-26
AR108333A1 (es) 2018-08-08

Similar Documents

Publication Publication Date Title
CO2018011087A2 (es) Tratamiento de dermatitis atópica canina
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
BR112018001187A2 (pt) materiais e métodos para melhorar as respostas imunes e funções de barreira de pele e/ou mucosa
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018000451A1 (es) Composiciones de micropartículas que comprenden saflufenacil
BR112017024940A2 (pt) composições de óleo essencial e seu método
BR112018003967A2 (pt) tratamento de hipersensibilidade à picada de inseto
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
PH12017500003A1 (en) Vaccine composition for classical swine fever from plant and manufacturing method thereof
CL2016002281A1 (es) Anticuerpos de il-21
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
BR112017012495A2 (pt) composições e métodos para controle de pragas de plantas
BR112016012599A2 (pt) composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus
ECSP19008417A (es) Anticuerpos con inmunogenicidad baja y usos de estos
CO2017002614A2 (es) Vacuna emulsionada para obtener formulaciones de inmunoglobulinas igy concentradas; procesos y usos de las mismas.
ECSP18070641A (es) Anticuerpos para il-17c
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
BR112017008097A2 (pt) método para tratar condições oculares
CL2016001906A1 (es) Vacunas contra el reovirus aviar.
BR112017011076A2 (pt) métodos e composições para prevenir ou reduzir infecções de plantas cultivadas por agentes patogênicos fúngicos e bacterianos
BR112017012362A2 (pt) composições e métodos para controle de pragas de plantas.